Published in Br J Haematol on July 05, 2006
Dendritic cell-based immunotherapy for myeloid leukemias. Front Immunol (2013) 0.90
The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases. Intractable Rare Dis Res (2012) 0.75
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43
A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods (1994) 2.06
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet (2002) 2.01
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.75
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
Outcome of ICU treatment in invasive aspergillosis. Intensive Care Med (1996) 1.52
Nasal T-cell lymphoma: a clinicopathological and immunophenotypic analysis of 13 cases. Histopathology (1995) 1.51
Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera. Eur J Nucl Med (1992) 1.48
Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol (2006) 1.46
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia (1999) 1.44
BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood (1995) 1.24
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia (2004) 1.23
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol (1998) 1.21
New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure. Neth J Med (2011) 1.07
Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood (1996) 1.06
Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study. J Immunol Methods (1991) 1.06
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology (2003) 1.03
Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood (1999) 1.03
Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia (2004) 1.01
Long-term effects of vincristine on the peripheral nervous system. J Neurooncol (1993) 1.00
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia (2011) 1.00
Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol (1996) 0.97
Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol (2005) 0.97
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia (2011) 0.95
Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant (2010) 0.95
Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. Leukemia (2004) 0.94
Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia (2010) 0.93
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res (2013) 0.93
Sequence analysis of cDNA derived from reticulocyte mRNAs coding for Rh polypeptides and demonstration of E/e and C/c polymorphisms. Vox Sang (1994) 0.92
Highly variable clinical manifestations in a large family with a novel GATA2 mutation. Leukemia (2013) 0.91
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res (1995) 0.91
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res (2000) 0.90
Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol (2008) 0.89
Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia (2011) 0.89
MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. Immunobiology (2006) 0.89
Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med (1993) 0.89
Cell cycle specific effects of tumor necrosis factor alpha in monocyte mediated leukemic cell death and the role of beta 2-integrins. Cancer Res (1993) 0.88
Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol (2006) 0.87
Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med (1993) 0.87
Noncutaneous T-cell lymphomas. Recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis. Cancer (1993) 0.87
Gallium-67 radiotoxicity in human U937 lymphoma cells. Br J Cancer (1993) 0.86
Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. Leukemia (2012) 0.86
Apoptosis in tumor necrosis factor-alpha-dependent, monocyte-mediated leukemic cell death: a functional, morphologic, and flow-cytometric analysis. Exp Hematol (1993) 0.86
Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: relation between latent membrane protein-1 positivity and clinical course. Histopathology (1993) 0.86
Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia (2003) 0.86
Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant (2002) 0.85
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica (2012) 0.85
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer (1994) 0.85
Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br J Haematol (2000) 0.84
A prospective study of untunnelled subclavian vein catheters in hematooncology patients. Neth J Med (1991) 0.84
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol (2012) 0.84
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol (1999) 0.83
Chemotherapy in non-Hodgkin's lymphoma during pregnancy. Neth J Med (1991) 0.83
Radiotoxicity of 67-gallium on myeloid leukemic blasts. Leuk Res (1995) 0.83
Identification of genes potentially involved in disease transformation of CML. Leukemia (2005) 0.83
A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J Clin Pathol (1999) 0.83
Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells. Leukemia (2006) 0.83
Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia (2001) 0.82
Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol (1998) 0.82
High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk Res (2011) 0.82
Genotyping by morphology... Blood (2011) 0.82
Isolation and purification of large quantities of fresh human Kupffer cells, which are cytotoxic against colon carcinoma. Hepatology (1995) 0.82
Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha. Haematologica (2006) 0.82
Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies. Eur J Haematol (1991) 0.81
Therapeutic potential of intravenous 67-gallium in non-Hodgkin's lymphoma. Eur J Haematol (1993) 0.81
Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants. Bone Marrow Transplant (2001) 0.81
Monocytic differentiation induction of HL-60 cells by MC 903, a novel vitamin D analogue. Leuk Res (1992) 0.80
Relation of CD30 expression to survival and morphology in large cell B cell lymphomas. J Clin Pathol (1994) 0.80
Adult respiratory distress syndrome in leptospira icterohaemorrhagiae infection. Intensive Care Med (1985) 0.80
A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. Arch Neurol (1992) 0.80
Intraspinal extramedullary haematopoiesis in a patient with myelofibrosis. Neth J Med (2002) 0.80
Costs of intensive treatment and follow-up of patients with multiple myeloma. Anticancer Drugs (1998) 0.80
Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant (1996) 0.80
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia (2005) 0.80
High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2001) 0.80
High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study. Br J Cancer (1995) 0.80
IMVP-16 followed by high dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma. Hematol Oncol (1992) 0.79
Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood. Leukemia (2013) 0.79
Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome. Leuk Res (2004) 0.79
The role of BCL-2 and bax protein in monocyte-mediated apoptosis in human leukemic cell lines. Exp Hematol (1996) 0.79
Spectrophotometric determination of clonogenic capacity of leukemic cells in a semisolid microtiter culture system. Exp Hematol (1993) 0.79
Comorbidity and treatment decision-making in elderly non-Hodgkin's lymphoma patients: a survey among haematologists. Neth J Med (2014) 0.79